 Orphazyme AS NASDAQ: ORPH expects FY21 sales of DKK 35 million DKK 37 million, compared to the previous guidance of DKK 30 million DKK 40 million. It anticipates operating expenses of DKK 665 million DKK 675 million, lower than the earlier outlook of DKK 700 million DKK 720 million. 